Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Cerebral Ischemic Events Associated with Endocarditis, Retinal Vascular Disease, & Lupus Anticoagulant
Am J Med 90:299-309, Pope,J.M.,et al, 1991
Cerebrovascular Disease & Antiphospholipis Antibodies in SLE, Lupus-Like Dis, & Primary Antiphospholipid Synd
Am J Med 86:391-399, Asherson,R.A.,et al, 1989
Clinicopath Conf
Antiphospholipid-Antibody Syndrome, ANA-Negative Systemic Lupus Erythematosus, Case Study 37-1988, N, JM :699-712,1988., 1988
TIA, Stroke, & Mitral Valve Prolapse
Neurol 29:886-889, Watson,R.T., 1979
Neuro CPC of MGH
Cerebral Embolism & Infarction, NEJM 267:1084-109162., , 1962